SS-31
Mitochondrial PeptidesPreclinicalAlso known as: Elamipretide, MTP-131, Bendavia, Szeto-Schiller peptide 31, D-Arg-Dmt-Lys-Phe-NH2, Mitochondrial-targeted tetrapeptide
SS-31 (elamipretide; MTP-131; formerly Bendavia; chemical sequence D-Arg-Dmt-Lys-Phe-NH2 with dimethyltyrosine at position 2) is a first-in-class aromatic-cationic tetrapeptide designed to selectively target the inner mitochondrial membrane and bind cardiolipin, the signature mitochondrial phospholipid essential for cristae architecture, electron transport chain organization, and respiratory function. Invented in the late 1990s and early 2000s in the laboratories of Hazel Szeto and Peter Schiller at Cornell and the Clinical Research Institute of Montreal, SS-31 belongs to a family of "Szeto-Schiller" peptides that exploit a precise combination of alternating aromatic and basic amino acid residues to achieve both membrane permeability (crossing the plasma membrane without transporters or receptors) and mitochondrial specificity (preferential accumulation on the inner mitochondrial membrane at concentrations 1,000- to 5,000-fold higher than in cytosol).
Overview
At A Glance
SS-31's mechanism of action is distinctive among mitochondrial interventions because it exploits a fundamental physical property of the inner mitochondrial membrane — the high concentration of cardiolipin, a signature mitochondrial anionic phospholipid — to achieve organelle-spec…
Mechanism of Action
SS-31's mechanism of action is distinctive among mitochondrial interventions because it exploits a fundamental physical property of the inner mitochondrial membrane — the high concentration of cardiolipin, a signature mitochondrial anionic phospholipid — to achieve organelle-specific targeting without requiring transporters, receptors, or delivery technology. Understanding the mechanism in detail clarifies both what SS-31 can and cannot do, why it works in certain contexts and fails in others, and how it differs from and complements other mitochondrial interventions.
Structure and design: SS-31 is a tetrapeptide with the sequence D-Arginine - 2',6'-dimethyltyrosine - Lysine - Phenylalanine - amide. Three design features drive its mitochondrial selectivity: (1) alternating aromatic-cationic residue pattern, which enables both membrane permeability (aromatic groups) and electrostatic attraction to negatively charged membranes (cationic residues); (2) dimethyltyrosine (Dmt) at position 2, providing bulk aromatic surface for membrane interaction and resistance to enzymatic cleavage; (3) D-amino acid at position 1 (D-arginine), further improving metabolic stability. The tetrapeptide has a net positive charge of +3 at physiological pH, which drives its accumulation at the highly negatively charged inner mitochondrial membrane (cardiolipin has four negatively charged phosphate groups per molecule, contributing to a strong negative surface potential at the IMM). Unlike mitochondrial targeting achieved through triphenylphosphonium (TPP) cation conjugation — as used in MitoQ and related compounds — SS-31's mitochondrial selectivity is driven by peptide structure alone, with multiple independent studies confirming high IMM concentrations without the membrane potential dissipation sometimes associated with TPP-conjugated compounds.
Cardiolipin binding and stabilization: Cardiolipin is a unique phospholipid with four acyl chains (versus the two in standard phospholipids) and a dimeric structure that organizes the inner mitochondrial membrane into its characteristic cristae morphology. Cardiolipin interacts directly with cytochrome c, coenzyme Q10 binding sites on Complex III, ATP synthase, the phosphate carrier, the adenine nucleotide translocator, and other respiratory chain and transport proteins. In healthy mitochondria, cardiolipin anchors cytochrome c to the inner membrane surface, enabling efficient electron transfer between Complexes III and IV. Under oxidative stress, cardiolipin undergoes peroxidation (fatty acid oxidation), which releases cytochrome c into the intermembrane space and ultimately into the cytosol, triggering both respiratory dysfunction and caspase-mediated apoptosis. SS-31 binds cardiolipin at a specific stoichiometry, stabilizes the cardiolipin-cytochrome c interaction, and prevents peroxidation-induced cytochrome c release. This stabilization preserves the structural integrity of the inner membrane, maintains cristae morphology, and sustains the supramolecular organization of the respiratory chain supercomplexes (Complexes I+III+IV "respirasomes") that improve electron flow and minimize electron leak.
Reduction of ROS at the source: Approximately 1-5 percent of electrons passing through the electron transport chain leak out of the normal electron flow and reduce molecular oxygen to superoxide, the primary mitochondrial ROS species. Superoxide generation occurs primarily at Complex I (NADH dehydrogenase) and Complex III (cytochrome c reductase), with rates modulated by membrane potential, substrate availability, and supercomplex integrity. When cardiolipin peroxidation disrupts respiratory chain organization, electron leak increases dramatically, producing a vicious cycle where more ROS leads to more cardiolipin damage, which leads to more ROS. SS-31, by preserving cardiolipin structure and supercomplex integrity, reduces electron leak and lowers baseline ROS production. This is a fundamentally different mechanism from that of conventional antioxidants like NAC, CoQ10, or vitamin E, which scavenge ROS after they are produced. SS-31 addresses ROS at its source rather than downstream, which may explain its efficacy in contexts where conventional antioxidants have failed (conventional antioxidant trials for cardiovascular disease, for example, have shown generally disappointing results despite strong mechanistic rationale).
Preservation of mitochondrial respiration and ATP synthesis: By stabilizing the electron transport chain and reducing cardiolipin damage, SS-31 preserves respiratory capacity measured as oxygen consumption, ATP production, and respiratory control ratios in isolated mitochondria and intact cells. In aged tissues with declining mitochondrial function, SS-31 treatment can restore respiratory capacity toward young values in multiple preclinical models. In acute ischemia-reperfusion injury, SS-31 pretreatment preserves post-ischemic recovery of mitochondrial function, reducing infarct size and tissue damage. In chronic mitochondrial diseases with genetic defects in cardiolipin remodeling (Barth syndrome) or electron transport chain components, SS-31 provides partial compensation by optimizing the remaining functional machinery.
Prevention of mitochondrial permeability transition pore (mPTP) opening: The mPTP is a high-conductance channel that opens under conditions of mitochondrial calcium overload, oxidative stress, and membrane damage, producing catastrophic loss of membrane potential, respiratory failure, and release of pro-apoptotic factors. mPTP opening is central to ischemia-reperfusion injury and many forms of cell death. Cardiolipin stabilization by SS-31 increases the threshold for mPTP opening, contributing to cellular protection in ischemic and other stress contexts.
Effects on mitochondrial dynamics (fusion, fission, mitophagy): Mitochondria undergo continuous cycles of fusion (joining) and fission (dividing), with damaged mitochondria targeted for mitophagy (selective autophagy of mitochondria). Cardiolipin externalization on the outer mitochondrial membrane serves as a "kill signal" that recruits LC3 and initiates mitophagy of damaged organelles. SS-31's cardiolipin effects may modulate mitophagy signaling, though the net effect (whether SS-31 increases or decreases mitophagy rates) depends on tissue context and is not completely characterized. Mechanistic complementarity with urolithin A, a direct mitophagy inducer, suggests possible synergy in clearing damaged mitochondria while protecting healthy ones.
Tissue distribution and pharmacokinetics: SS-31 accumulates preferentially in tissues with high mitochondrial density and activity — heart, skeletal muscle, kidney, liver, and brain. Tissue-to-plasma ratios reported in preclinical studies range from 10- to 100-fold, with heart showing the highest accumulation. The plasma half-life after subcutaneous injection is approximately 2-4 hours in humans, but tissue residence time is longer due to binding to cardiolipin. This pharmacokinetic profile supports once-daily dosing for chronic applications, though absolute tissue exposure duration depends on cardiolipin turnover in each tissue. Metabolic clearance occurs through aminopeptidase-mediated hydrolysis, producing inactive fragments excreted renally. No significant CYP450 interactions have been reported, making drug-drug interactions less problematic than with many small-molecule drugs.
Non-classical effects: Beyond the primary cardiolipin-stabilizing mechanism, SS-31 has been reported to modulate several downstream signaling pathways including AMPK activation (consistent with improved cellular energy status), reduced NF-κB-driven inflammation, improved endothelial function, modulation of apoptotic signaling, and preservation of stem cell function in aged tissues. Whether these effects are direct consequences of SS-31 binding or indirect consequences of improved mitochondrial function is often difficult to parse experimentally. The functional relevance to therapeutic applications is real regardless of upstream versus downstream causation.
What SS-31 does not do: SS-31 does not increase mitochondrial biogenesis directly (that's the role of PGC-1α activators and endurance exercise). It does not supply NAD+ precursor (that's NMN and NR). It does not provide electron transport chain cofactors (that's CoQ10, complex I/II substrates like succinate, and related mitochondrial nutrients). It does not clear damaged mitochondria (that's mitophagy, enhanced by urolithin A, rapamycin, and exercise). Understanding what SS-31 does not do clarifies why it complements rather than replaces these other mitochondrial interventions in a complete stack.
Overview
SS-31 (elamipretide; MTP-131; formerly Bendavia; chemical sequence D-Arg-Dmt-Lys-Phe-NH2 with dimethyltyrosine at position 2) is a first-in-class aromatic-cationic tetrapeptide designed to selectively target the inner mitochondrial membrane and bind cardiolipin, the signature mitochondrial phospholipid essential for cristae architecture, electron transport chain organization, and respiratory function. Invented in the late 1990s and early 2000s in the laboratories of Hazel Szeto and Peter Schiller at Cornell and the Clinical Research Institute of Montreal, SS-31 belongs to a family of "Szeto-Schiller" peptides that exploit a precise combination of alternating aromatic and basic amino acid residues to achieve both membrane permeability (crossing the plasma membrane without transporters or receptors) and mitochondrial specificity (preferential accumulation on the inner mitochondrial membrane at concentrations 1,000- to 5,000-fold higher than in cytosol). The resulting molecule is a rare pharmacological tool: a small peptide that, unlike most peptides, does not require specialized delivery technology to reach its intracellular target, and unlike most small molecules, does not distribute indiscriminately across cellular compartments.
The core therapeutic rationale for SS-31 rests on the centrality of mitochondrial dysfunction in aging and a wide range of human diseases. Mitochondria are the primary sites of ATP production, calcium buffering, apoptosis regulation, iron-sulfur cluster biogenesis, steroidogenesis, and reactive oxygen species (ROS) generation. Age-related decline in mitochondrial function — manifesting as reduced respiratory capacity, increased ROS production, impaired calcium handling, and accumulating mtDNA damage — contributes to sarcopenia, cardiac dysfunction, neurodegeneration, insulin resistance, and impaired tissue regeneration. In specific pathological contexts, acute mitochondrial dysfunction drives ischemia-reperfusion injury following myocardial infarction, stroke, and organ transplantation; chronic mitochondrial dysfunction defines primary mitochondrial diseases (Barth syndrome, Leber hereditary optic neuropathy, mitochondrial myopathies); and maladaptive mitochondrial changes contribute to age-related macular degeneration, chronic kidney disease, heart failure, and neurodegeneration. SS-31's ability to selectively reach the inner mitochondrial membrane and stabilize cardiolipin-dependent machinery makes it a mechanistically attractive intervention across this broad disease landscape.
Commercially, SS-31 is developed by Stealth BioTherapeutics (originally Stealth Peptides, Inc.) as elamipretide, administered by subcutaneous injection at 40 mg daily in most clinical trial protocols. It has been studied in key and pilot trials across multiple indications including Barth syndrome (EMBARK/TAZPOWER), primary mitochondrial myopathy (MMPOWER-3), Leber hereditary optic neuropathy (ReSIGHT/REFOCUS-LHON), dry age-related macular degeneration and geographic atrophy (ReCLAIM/ReCLAIM-2), hypertrophic cardiomyopathy, Friedreich ataxia, and heart failure with preserved ejection fraction. As of this writing, elamipretide has not achieved broad regulatory approval in major markets, with several trials failing their primary endpoints despite biomarker signals suggesting mitochondrial engagement, and others showing preliminary promise but requiring larger confirmatory studies. In 2024, Stealth BioTherapeutics received FDA approval for elamipretide specifically for Barth syndrome, a rare genetic mitochondrial disorder, representing the first regulatory approval for a cardiolipin-targeting therapy. For broader age-related applications, evidence remains investigational and consumer use occurs outside regulatory approval pathways.
The longevity and biohacking communities have adopted SS-31 for off-label mitochondrial tuning despite its investigational status, treating it as a premium tool for users with specific mitochondrial concerns — severe fatigue, exercise intolerance, early neurodegenerative symptoms, macular health, or general mitochondrial support — who have the resources and risk tolerance to pursue experimental peptide therapy. The adoption pattern parallels that of other peptides from the research pharmacology pipeline: users obtain SS-31 through research chemical suppliers or specialty compounding pharmacies, reconstitute lyophilized peptide with bacteriostatic water, and administer subcutaneous injections daily or several times weekly. This approach sits squarely in the experimental/off-label zone of personal pharmacology, with meaningful limitations in safety monitoring, product quality verification, and individualized efficacy assessment that users should acknowledge explicitly before pursuing.
Mechanistically, SS-31 differs from conventional antioxidants like NAC, CoQ10, or curcumin in important ways. Classical antioxidants distribute broadly across cellular compartments and neutralize ROS through direct radical scavenging. SS-31 is not primarily a direct antioxidant — it has weak intrinsic scavenging activity — but rather a mitochondrial structural stabilizer that preserves cardiolipin-cytochrome c interactions, maintains electron transport chain organization on the inner mitochondrial membrane, and prevents the cardiolipin peroxidation cascade that both disrupts respiration and triggers apoptosis. The functional consequence is reduced ROS generation at its source (the electron transport chain), preserved respiratory capacity, maintained mitochondrial calcium handling, and resistance to opening of the mitochondrial permeability transition pore. In essence, SS-31 works upstream of where conventional antioxidants work, stabilizing the machinery that generates ROS rather than neutralizing ROS after production. This distinction matters therapeutically because SS-31 addresses causes of mitochondrial dysfunction (structural membrane disruption, cardiolipin peroxidation) while conventional antioxidants address consequences (accumulated ROS), and it explains why SS-31 sometimes shows effects in conditions where antioxidant supplementation has failed.
Clinical context is important for framing expectations. Primary mitochondrial diseases are rare conditions where a single gene defect disrupts mitochondrial function fundamentally — Barth syndrome involves tafazzin gene mutations that impair cardiolipin remodeling, producing the very membrane instability that SS-31 addresses mechanistically. In such rare diseases, SS-31 has a specific mechanistic rationale with preliminary clinical support. For general aging, sarcopenia, or cognitive decline in otherwise healthy individuals, the mechanistic case is that age-associated decline in cardiolipin integrity and mitochondrial function contributes to phenotypes and that SS-31 should correct these subtle defects. The evidentiary case, however, is much weaker. No large human trial has demonstrated that SS-31 meaningfully extends health-span or prevents age-related decline in otherwise-healthy adults, and some high-profile trials in conditions like heart failure with preserved ejection fraction or hypertrophic cardiomyopathy have failed to show clinical benefit despite biomarker signals. Users should calibrate expectations: SS-31 has strong mechanistic credentials, specific proven utility in Barth syndrome, promising signals in several investigational indications, and uncertain magnitude of benefit for general anti-aging use. It is not a panacea for mitochondrial aging, and its high cost (pharmaceutical-grade elamipretide runs thousands of dollars per month; research peptide versions are less expensive but of uncertain quality) places practical constraints on adoption.
SS-31 integrates into a mitochondrial-focused longevity stack alongside NMN or NR (NAD+ precursors supporting sirtuin and complex I activity), CoQ10 (electron transport chain cofactor and mitochondrial antioxidant), creatine (cellular energetics), omega-3 fatty acids (mitochondrial membrane composition), urolithin A (mitophagy inducer), and MOTS-c or humanin (mitochondrial-derived peptides with complementary effects on insulin sensitivity and neuronal protection). The stack addresses mitochondrial function from multiple angles: cardiolipin stabilization (SS-31), NAD+ supply (NMN/NR), electron transport function (CoQ10), substrate availability (creatine, carnitine), membrane composition (omega-3), turnover and quality control (urolithin A, rapamycin), and signaling (MOTS-c, humanin). Users pursuing serious mitochondrial tuning may use several of these together, though the incremental benefit of stacking SS-31 on top of a solid foundation of simpler interventions is not established and may be modest given the saturation of available mitochondrial benefit from foundational approaches.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Contraindications for SS-31 (elamipretide) reflect a combination of specific safety concerns documented in clinical trials, theoretical risks based on mechanism and pharmacology, and general caution appropriate for investigational peptide therapy. Because SS-31 remains investigational for most uses and consumer adoption operates outside regulatory approval pathways, users should approach contraindications conservatively.
Pregnancy: SS-31 should not be used during pregnancy. No adequate safety studies in pregnant women exist, and the theoretical concerns about peptide exposure during fetal mitochondrial development argue for avoidance. Women of reproductive potential using SS-31 should use reliable contraception and discontinue SS-31 if pregnancy occurs or is planned. Women with Barth syndrome or other specific mitochondrial diseases of reproductive age should consult mitochondrial specialists and reproductive medicine physicians before making decisions about continued use.
Lactation: SS-31 should not be used during breastfeeding. Whether elamipretide or its metabolites are excreted into breast milk is unclear; given the theoretical potential for effects on infant mitochondrial development and the absence of pediatric safety data in this context, avoidance is appropriate. Women completing SS-31 regimens before pregnancy should allow adequate washout time before conception; evidence-based washout guidance is not established but several half-lives of the compound (tissue half-life in weeks) would be conservative.
Active severe cardiac disease without cardiology oversight: While SS-31 has been studied in cardiac disease (heart failure, hypertrophic cardiomyopathy), its effects in severe cardiac disease can be complex. Users with severe heart failure, unstable cardiac disease, recent myocardial infarction, or significant cardiac arrhythmia should not start SS-31 without cardiology consultation and oversight. The investigational status of SS-31 in cardiac applications means that informed medical oversight is essential for users with meaningful cardiac disease.
Known peptide allergy: Users with documented severe allergic reactions to peptide medications (certain GLP-1 agonists, insulin, other peptide therapeutics) should not use SS-31 without allergy specialist consultation. Cross-reactivity with specific peptides is variable, but peptide allergy history increases risk of reaction to new peptide introductions.
Active cancer without oncology approval: Cancer cells often have altered mitochondrial biology, and SS-31's effects on mitochondrial function could interact with cancer biology in unpredictable ways. Users with active cancer should not use SS-31 without discussion with their oncologist. Cancer in remission may allow SS-31 use but still warrants oncology discussion before starting.
Active severe infection or sepsis: Systemic infection alters mitochondrial function dramatically; SS-31's effects during sepsis or severe systemic infection have not been well-characterized. Users with active severe infection should not initiate SS-31 and should pause ongoing use during severe illness until recovery.
Active autoimmune disease on aggressive immunomodulation: Users on high-dose immunosuppressants, biologic agents for autoimmune disease, or active immunotherapy should discuss SS-31 with their rheumatologist or immunologist before use. Interactions are theoretical but warrant specialist input.
Pediatric use: Outside specific clinical trial contexts and Barth syndrome approval in adolescent age ranges, pediatric use of SS-31 for longevity or off-label indications is not appropriate. No established safety or efficacy data for general pediatric use exists.
Research peptide product concerns: Users obtaining SS-31 from research chemical suppliers or unverified sources assume additional risks related to product quality, purity, contamination, and identity. Severe reactions to contaminated or mislabeled products are possible and would not reflect intrinsic SS-31 safety. Users should seek the highest quality sources accessible (pharmaceutical-grade elamipretide through specialty pharmacies where feasible; reputable research suppliers with third-party certificates of analysis as second choice) and exercise caution with unverified products.
Severe hepatic impairment: SS-31 pharmacokinetics in severe liver disease have not been well-characterized. Aminopeptidase metabolism and renal excretion dominate SS-31 clearance, but users with severe hepatic impairment (Child-Pugh C cirrhosis) should exercise caution and consult hepatology.
Severe renal impairment: Renal excretion is the primary route for SS-31 metabolites. Users with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or dialysis-dependent kidney disease should consult nephrology before starting SS-31. Dose adjustment may be appropriate.
Active central nervous system disease: Users with active neurodegenerative disease in acute phases, recent stroke, severe seizure disorders, or active CNS infections should exercise particular caution and coordinate with neurology.
Perioperative period: SS-31 should generally be paused for major elective surgery unless specifically indicated for perioperative use (for example, cardiac surgery in Barth syndrome patients under specialist direction). Resume SS-31 after recovery.
Concurrent investigational therapies: Users participating in clinical trials should disclose all supplements and off-label therapies to trial investigators; most clinical trials prohibit concurrent investigational therapies that could confound results or safety monitoring.
Specific drug interactions to consider: Theoretical interactions with drugs affecting mitochondrial function (metformin, statins, valproate, some antiretrovirals like NRTIs) have not been systematically studied. Most interactions appear clinically modest. Users on these drugs should review with physician but do not necessarily need to avoid SS-31.
Age extremes: No specific evidence argues against use in healthy older adults (ages 60-90) who are otherwise appropriate candidates. Very elderly users (90+) have limited data and should individualize based on overall health status. Younger adults (under 30) without specific clinical indications have less rationale for SS-31 use and should consider whether the experimental nature of the intervention matches their goals.
Quality-of-life versus extension considerations: For patients near end of life from terminal disease, the cost-benefit calculus for SS-31 use shifts; some specialist physicians may integrate SS-31 into palliative mitochondrial support protocols, but this is an advanced clinical decision rather than general consumer use.
When to discuss SS-31 with a physician before starting: All users with chronic medical conditions, users on multiple prescription medications, users with cancer history, users with active clinical research participation, users with complex cardiovascular, neurologic, or metabolic disease, users approaching major medical procedures. For most otherwise-healthy adults pursuing SS-31 for general mitochondrial optimization, specific medical clearance may not be required, but physician awareness of supplementation is good practice during periodic health visits.
Final framing: SS-31 is an investigational peptide therapeutic with regulatory approval in one rare disease (Barth syndrome) and investigational status in all other uses. Off-label consumer use involves assumption of unknown risks in exchange for uncertain benefits. Users should approach with appropriate respect for the limitations of current evidence, exercise conservatism in the face of uncertainty, and maintain honesty about the experimental nature of the intervention.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$45.00
up to $139.00
$2.7800
1
3
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
SS-31 10mg | vial | 1 vial● Out of Stock | $45.00BEST | $4.500 | — | Sign in for stock alert |
|
|
SS-31 35mg | vial | 1 vial● In Stock | $99.00 | $2.829 | — | |
|
|
SS-31 50mg | vial | 1 vial● In Stock | $139.00VALUE | $2.780 | — |
Tracking since Apr 22, 2026 · 3 data points
Vendors Selling SS-31
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for SS-31
Research Score
4 PubMed studies
Quality Indicators
Data Completeness
75%Research Credibility
Limited research available
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is SS-31 and how does it differ from other mitochondrial supplements?
SS-31 (elamipretide; MTP-131; formerly Bendavia) is a synthetic aromatic-cationic tetrapeptide designed by Hazel Szeto and Peter Schiller in the early 2000s to selectively target the inner mitochondrial membrane. Its sequence is D-Arg-Dmt-Lys-Phe-NH2 (with dimethyltyrosine at position 2). Unlike conventional mitochondrial supplements, SS-31 operates through a unique mechanism: it binds cardiolipin, a signature phospholipid of the inner mitochondrial membrane, and stabilizes cardiolipin-cytochrome c interactions and electron transport chain supercomplex organization. This preserves mitochondrial respiration, reduces ROS generation at its source (rather than scavenging ROS after production like conventional antioxidants), and protects mitochondrial integrity under stress. CoQ10 provides electron transport chain cofactor support; NMN elevates NAD+ for sirtuin and complex I activity; creatine buffers cellular ATP; urolithin A induces mitophagy. SS-31 complements rather than replaces these — it addresses mitochondrial membrane integrity specifically, a mechanism not covered by other interventions. It is administered by subcutaneous injection (typically 40 mg daily), remains investigational for most uses, and received FDA approval in 2024 specifically for Barth syndrome.
Has SS-31 been approved by the FDA? What does the clinical evidence show?
In 2024, Stealth BioTherapeutics received FDA approval for elamipretide specifically for Barth syndrome, an X-linked rare genetic disease caused by TAZ gene mutations that disrupt cardiolipin remodeling. This represented the first regulatory approval for a cardiolipin-targeting therapy. The approval was based on TAZPOWER (Reid Thompson 2021, PMID 33769413) and EMBARK extension data showing improved 6-minute walk distance and functional capacity. Outside Barth syndrome, elamipretide has investigational status with mixed trial results. The MMPOWER-3 phase 3 trial in primary mitochondrial myopathy (Karaa 2020, PMID 32269115) failed its primary endpoint despite favorable trends. The ReCLAIM-2 phase 2b trial in geographic atrophy from dry AMD did not meet primary endpoints. Trials in hypertrophic cardiomyopathy and heart failure with preserved ejection fraction have also produced disappointing results. Preclinical data across aging and mitochondrial dysfunction models are broadly supportive. For longevity and off-label use, users extrapolate from preclinical data and the Barth syndrome mechanism, acknowledging that definitive human efficacy evidence for general anti-aging use does not exist. Honest framing: strong mechanistic credentials, specific approval in rare disease, mixed trial results in larger indications, and investigational status for broader consumer use.
How is SS-31 administered and what is the typical dose?
SS-31 is administered by subcutaneous injection, typically once daily. The standard clinical trial dose is 40 mg daily, used in MMPOWER-3, TAZPOWER, ReCLAIM-2, and other pivotal trials. Common user doses range from 20-40 mg daily, with some advanced protocols using up to 60-80 mg daily under physician supervision. The compound is supplied as lyophilized powder in multi-dose vials (typically 10-50 mg), reconstituted with bacteriostatic water before use. For a 20 mg vial with 1 mL bac water (20 mg/mL concentration), a 40 mg dose requires 2 mL, injected subcutaneously into abdominal fat, thigh, or upper arm with an insulin syringe. Injection sites should be rotated across multiple locations to minimize local reactions. Morning administration after breakfast is preferred by most users. Reconstituted solutions store refrigerated and are typically used within 28-30 days. Some users reduce frequency to 5-6 days weekly for cost management. Dose-response relationships in humans are not well-characterized, and 40 mg daily represents the reference dose rather than a proven optimum.
What are the common side effects of SS-31?
SS-31 (elamipretide) has been generally well-tolerated in clinical trials, with adverse events dominated by injection site reactions. The most common effects are local: injection site redness, swelling, itching, transient pain, occasional bruising. These are typically mild and self-limited, minimized by proper injection technique, site rotation, and bringing the reconstituted solution to room temperature before injection. Less common effects include mild gastrointestinal symptoms (nausea, abdominal discomfort, changes in bowel habits), mild headache or dizziness (often resolving within 1-2 weeks), and transient fatigue in some users early in treatment. Systemic serious adverse events are uncommon. Theoretical concerns include allergic/hypersensitivity reactions (rare but possible with any injectable peptide), cardiac effects (most data in patients with pre-existing cardiomyopathy, so attribution to SS-31 in healthy users is challenging), and unknown long-term effects given limited duration of consumer use. Research-grade peptide products from unverified suppliers carry additional risks related to purity and contamination that are separate from intrinsic drug safety. Users should discontinue and seek medical evaluation for any severe reaction, signs of infection at injection sites, or unexplained new systemic symptoms.
Can I stack SS-31 with NMN, CoQ10, urolithin A, or other mitochondrial supplements?
Yes, SS-31 stacks well with other mitochondrial interventions because of its unique cardiolipin-stabilizing mechanism that does not duplicate other approaches. A comprehensive mitochondrial stack addresses: cardiolipin/membrane integrity (SS-31), NAD+ supply (NMN or NR), electron transport chain cofactors (CoQ10 as ubiquinol), substrate availability (creatine, carnitine), quality control (urolithin A for mitophagy, rapamycin for autophagy), and membrane composition (omega-3 fatty acids for EPA/DHA). These interventions address different aspects of mitochondrial biology without meaningful redundancy. Typical stacking includes daily NMN 500-1000 mg + ubiquinol 100-300 mg + creatine 5 g + omega-3 2-3 g EPA/DHA + urolithin A 500-1000 mg, with SS-31 40 mg subcutaneous daily layered on top. Other mitochondrial peptides like MOTS-c and humanin operate through distinct signaling mechanisms and can be stacked with SS-31 for broader coverage, though costs accumulate. Users should layer one new intervention at a time to establish individual tolerability before combining.
Is SS-31 the same as research peptide SS-31 I can buy online?
Pharmaceutical-grade elamipretide (developed by Stealth BioTherapeutics) and research peptide SS-31 share the same chemical sequence but differ substantially in manufacturing standards, purity verification, regulatory oversight, and cost. Pharmaceutical elamipretide is manufactured under cGMP (current Good Manufacturing Practice) standards, batch-tested for identity/purity/sterility/endotoxin, and supplied through specialty pharmacies under appropriate medical oversight; cost runs thousands of dollars monthly at standard doses. Research peptide SS-31 from research chemical suppliers varies dramatically in quality: reputable suppliers may provide third-party certificates of analysis documenting identity and purity; less reputable suppliers may sell mislabeled, contaminated, or degraded products; costs typically $100-500 monthly. The risks of research peptide products include wrong peptide (sequence different from labeled), wrong concentration (label inaccurate), contamination (bacterial endotoxin, chemical residues), degradation products (inactive or toxic metabolites), and general quality variation. Users obtaining SS-31 from research sources should prioritize suppliers with third-party testing, verify certificates of analysis for each lot, and accept that product quality is inherently less assured than pharmaceutical-grade. For users with specific clinical indications (Barth syndrome, mitochondrial myopathy), pharmaceutical-grade elamipretide through specialty pharmacies or clinical trial participation is strongly preferred.
How long does it take to see benefits from SS-31, and what should I expect?
Expectations for SS-31 benefits depend heavily on the use case. For specific clinical indications where SS-31 has evidence (Barth syndrome), clinical trial data suggest improvements in functional capacity (6-minute walk distance, muscle strength) emerge over 4-12 weeks of treatment. For general longevity and off-label mitochondrial optimization in healthy users, expectations should be modest: subtle improvements in energy, exercise recovery, cognitive clarity, or general well-being may emerge over weeks to months but are difficult to distinguish from placebo response without biomarker confirmation. Dramatic acute effects are not expected and should raise concerns about placebo response or product quality issues. Biomarker changes (inflammatory markers, cardiac biomarkers, exercise metrics) may become apparent over 2-3 months of consistent dosing. Clinical outcome improvements in longevity applications accumulate over years and cannot be individually verified in short timeframes. A reasonable framing for off-label users: treat SS-31 as a small probabilistic bet on improved mitochondrial health over time, not as an acute therapeutic that will produce obvious transformation. Users without perceived benefit after 3-6 months of consistent use may reasonably discontinue and invest resources in other interventions. Users with specific mitochondrial-related symptoms (severe exercise intolerance, specific cardiomyopathy, neurodegeneration) have clearer domain-specific outcomes to track.
Is SS-31 safe for long-term use? What about chronic dosing over years?
Long-term safety data for SS-31 beyond clinical trial durations (typically weeks to months) is limited. Clinical trial exposure has extended to 1-2 years in some open-label extensions (TAZPOWER EMBARK for Barth syndrome) without emergence of unexpected safety signals, but consumer off-label use may extend to many years with uncertain implications. Theoretical concerns about chronic SS-31 use include: adaptive changes in mitochondrial biology with sustained cardiolipin stabilization, potential effects on mitochondrial heteroplasmy dynamics in users with mtDNA variants, altered mitochondrial biogenesis signaling under chronic exogenous support, and cumulative effects on less-characterized pathways. None of these theoretical concerns have materialized as clinical issues in available data, but the absence of long-term large-population data means safety cannot be definitively assured. Prudent practice includes periodic reassessment (every 6-12 months) of continued use benefit, willingness to take intermittent breaks to avoid continuous chronic exposure, monitoring of general health and laboratory parameters, and updating strategy as emerging evidence evolves. Users should not commit to indefinite SS-31 use without ongoing honest evaluation of benefit versus cost and theoretical risk.
Does SS-31 help with cardiovascular disease, heart failure, or cardiomyopathy?
SS-31 has been extensively studied in cardiovascular conditions with mixed results. Preclinical data strongly supported development in ischemia-reperfusion injury, heart failure, and cardiomyopathy. Early human trials showed biomarker improvements and some functional gains. However, larger pivotal trials in heart failure with preserved ejection fraction (HFpEF) and hypertrophic cardiomyopathy have generally not met primary efficacy endpoints. The disconnect between preclinical promise and clinical trial outcomes may reflect trial design issues, heterogeneity of cardiac disease populations, difficulty measuring clinically meaningful outcomes, or limitations of the underlying hypothesis. For Barth syndrome (which involves cardiomyopathy as a core feature), SS-31 has demonstrated functional benefits and received FDA approval, representing the clearest positive cardiac indication. For other cardiac conditions, users should view SS-31 as investigational with uncertain benefit, not as established therapy for heart failure or cardiomyopathy. Users with cardiac disease should not substitute SS-31 for evidence-based cardiac treatments (heart failure GDMT, revascularization, device therapy where indicated) but rather should discuss SS-31 as an adjunctive option with their cardiologist. The investigational status in cardiac disease means physician oversight is essential; self-directed off-label use in patients with serious cardiac disease is not appropriate.
What is the cost of SS-31, and is it affordable for long-term use?
SS-31 cost varies dramatically by source. Pharmaceutical-grade elamipretide (brand names used in clinical trials) through specialty compounding pharmacies or via specific indication approval typically costs several thousand dollars per month at the standard 40 mg daily dose. For Barth syndrome patients with insurance coverage or patient assistance programs, cost barriers may be reduced. For off-label longevity use, insurance typically does not cover the compound and full out-of-pocket cost applies. Research peptide SS-31 from specialty suppliers costs significantly less, typically $100-500 monthly depending on quality tier, supplier, and dose. This price differential reflects different manufacturing standards, quality verification, and regulatory oversight rather than different active compound. For long-term use, cost becomes a significant practical limitation. Users should honestly evaluate whether they can sustain intended protocol cost without financial strain. Cost-management strategies include lower doses (20 mg daily rather than 40 mg), reduced frequency (5 days weekly rather than daily), careful supplier selection to balance quality and cost, and periodic protocol breaks. For users pursuing multi-peptide stacks (SS-31 + MOTS-c + humanin + others), cumulative monthly costs can reach thousands of dollars. A sober cost-benefit framing: SS-31 is an expensive experimental peptide with uncertain benefit for general longevity use; allocating substantial resources to SS-31 over other evidence-based health interventions (exercise, sleep, nutrition, medical monitoring, simpler supplements) is a priority decision that should match individual values and budget realistically.
Research Tools
Side-by-Side Comparisons
All ComparisonsCompare SS-31 head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
